Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irofulven - Lantern Pharma/Oncology Venture AS

Drug Profile

Irofulven - Lantern Pharma/Oncology Venture AS

Alternative Names: 6-HMAF; 6-hydroxymethylacylfulvene; E 7850; HMAF; Irofulven-1; LP 100; MGI 114

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Dainippon Sumitomo Pharma; Eisai Co Ltd; Lantern Pharma; Oncology Venture A/S
  • Class Antineoplastics; Cyclopropanes; Indenes; Sesquiterpenes; Small molecules; Spiro compounds
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Renal cell carcinoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 25 Oct 2019 Pharmacodynamics results from the preclincial trial presented at the International Conference on Molecular Targets and Cancer Therapeutics 2019 (AACR-NCI-EORTC-2019)
  • 18 Oct 2018 Oncology Venture initiates enrolment in a phase II trial for Prostate cancer in Denmark (NCT03643107) (EudraCT2017-003549-72)
  • 04 Sep 2018 Oncology Venture plans a phase II trial for prostate cancer
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top